The clinical utility of mass spectrometry based protein assays

Lassman, Michael E.; McAvoy, Thomas; Chappell, Derek L; Lee, Anita Y.; Zhao, Xuemei; Laterza, Omar

doi:10.1016/j.cca.2016.05.027

Cited by 11 publications

(7 citation statements)

References 119 publications

(121 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is not to say that other (bio)molecular techniques are still not valuable in this context as they can be used as a first screening approach in a toxin-related bioterrorism scenario since it is highly probable that the toxin may not be pure and will be contaminated and carry some of the parent organism’s genetic material or other biomarkers of interest . Although only an overview of MS-based techniques and their application to toxin detection are presented here without in-depth explanation of all factors, it is important to appreciate the wide variety of equipment available, the different types of MS detectors in use, along with the large number of preparatory techniques and sample purification strategies that are applied for these purposes. − …”

Section: Physical Techniquesmentioning

confidence: 99%

Detecting Biothreat Agents: From Current Diagnostics to Developing Sensor Technologies

et al. 2018

View full text Add to dashboard Cite

Although a fundamental understanding of the pathogenicity of most biothreat agents has been elucidated and available treatments have increased substantially over the past decades, they still represent a significant public health threat in this age of (bio)terrorism, indiscriminate warfare, pollution, climate change, unchecked population growth, and globalization. The key step to almost all prevention, protection, prophylaxis, post-exposure treatment, and mitigation of any bioagent is early detection. Here, we review available methods for detecting bioagents including pathogenic bacteria and viruses along with their toxins. An introduction placing this subject in the historical context of previous naturally occurring outbreaks and efforts to weaponize selected agents is first provided along with definitions and relevant considerations. An overview of the detection technologies that find use in this endeavor along with how they provide data or transduce signal within a sensing configuration follows. Current "gold" standards for biothreat detection/diagnostics along with a listing of relevant FDA approved in vitro diagnostic devices is then discussed to provide an overview of the current state of the art. Given the 2014 outbreak of Ebola virus in Western Africa and the recent 2016 spread of Zika virus in the Americas, discussion of what constitutes a public health emergency and how new in vitro diagnostic devices are authorized for emergency use in the U.S. are also included. The majority of the Review is then subdivided around the sensing of bacterial, viral, and toxin biothreats with each including an overview of the major agents in that class, a detailed cross-section of different sensing methods in development based on assay format or analytical technique, and some discussion of related microfluidic lab-on-a-chip/point-of-care devices. Finally, an outlook is given on how this field will develop from the perspective of the biosensing technology itself and the new emerging threats they may face.

show abstract

Section: Physical Techniquesmentioning

confidence: 99%

Detecting Biothreat Agents: From Current Diagnostics to Developing Sensor Technologies

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The proteome can mainly be analyzed using MS or protein microarrays [ 53 , 59 ]. However, MS and protein separation allow rapid and accurate detection of hundreds of human proteins and peptides from a small amount of body fluid or tissue [ 59 , 60 , 61 ]. Recent studies showed promising results using proteome analysis to explore cystinuria [ 62 ], mucopolysaccharidoses [ 63 ], and liver mitochondrial functions [ 64 ].…”

Section: Omics Revolution In Translational and Clinical Contextsmentioning

confidence: 99%

“…They usually have different coverage of the sequenced regions [ 44 ]. MS platforms for proteomics and metabolomics have different sensitivities and chemical space coverage [ 61 , 76 ]. This is due to the differences in MS analyzer technology in terms of ionization method, resolution power, measurement accuracy, multi-dimensional separation, scan speed, dynamic range, and analysis throughput [ 55 , 56 , 76 ].…”

Section: Omics Revolution In Translational and Clinical Contextsmentioning

confidence: 99%

Omics-Based Strategies in Precision Medicine: Toward a Paradigm Shift in Inborn Errors of Metabolism Investigations

Tebani

Afonso

Marret

et al. 2016

IJMS

141

View full text Add to dashboard Cite

The rise of technologies that simultaneously measure thousands of data points represents the heart of systems biology. These technologies have had a huge impact on the discovery of next-generation diagnostics, biomarkers, and drugs in the precision medicine era. Systems biology aims to achieve systemic exploration of complex interactions in biological systems. Driven by high-throughput omics technologies and the computational surge, it enables multi-scale and insightful overviews of cells, organisms, and populations. Precision medicine capitalizes on these conceptual and technological advancements and stands on two main pillars: data generation and data modeling. High-throughput omics technologies allow the retrieval of comprehensive and holistic biological information, whereas computational capabilities enable high-dimensional data modeling and, therefore, accessible and user-friendly visualization. Furthermore, bioinformatics has enabled comprehensive multi-omics and clinical data integration for insightful interpretation. Despite their promise, the translation of these technologies into clinically actionable tools has been slow. In this review, we present state-of-the-art multi-omics data analysis strategies in a clinical context. The challenges of omics-based biomarker translation are discussed. Perspectives regarding the use of multi-omics approaches for inborn errors of metabolism (IEM) are presented by introducing a new paradigm shift in addressing IEM investigations in the post-genomic era.

show abstract

“…Ever since the first discovery of specific proteins associated with human disease , the field of protein chemistry and later proteomics sought to identify new and improved markers of disease and targets of therapies. While the instrumentation for analytical chemistry and MS has steadily improved, incorporation of this approach into preclinical investigation and clinical care has lagged . With notable exceptions, such as MS‐based detection of bacterial pathogens , and drug and metabolites , recent advances in MS remain largely confined to analytical chemistry laboratories .…”

Section: Introductionmentioning

confidence: 99%

Towards comprehensive and quantitative proteomics for diagnosis and therapy of human disease

Cifani

Kentsis

2016

Proteomics

View full text Add to dashboard Cite

Given superior analytical features, mass spectrometry proteomics is well suited for the basic investigation and clinical diagnosis of human disease. Modern mass spectrometry enables detailed functional characterization of the pathogenic biochemical processes, as achieved by accurate and comprehensive quantification of proteins and their regulatory chemical modifications. Here, we describe how high-accuracy mass spectrometry in combination with high-resolution chromatographic separations can be leveraged to meet these analytical requirements in a mechanism-focused manner. We review the quantification methods capable of producing accurate measurements of protein abundance and post-translational modification stoichiometries. We then discuss how experimental design and chromatographic resolution can be leveraged to achieve comprehensive functional characterization of biochemical processes in complex biological proteomes. Finally, we describe current approaches for quantitative analysis of a common functional protein modification: reversible phosphorylation. In all, current instrumentation and methods of high-resolution chromatography and mass spectrometry proteomics are poised for immediate translation into improved diagnostic strategies for pediatric and adult diseases.

show abstract

The clinical utility of mass spectrometry based protein assays

Cited by 11 publications

References 119 publications

Detecting Biothreat Agents: From Current Diagnostics to Developing Sensor Technologies

Detecting Biothreat Agents: From Current Diagnostics to Developing Sensor Technologies

Omics-Based Strategies in Precision Medicine: Toward a Paradigm Shift in Inborn Errors of Metabolism Investigations

Towards comprehensive and quantitative proteomics for diagnosis and therapy of human disease

Contact Info

Product

Resources

About